Catheter Precision Inc. (NYSE American: $VTAK ) Na
Post# of 91
(Total Views: 144)
Posted On: 10/11/2023 9:41:28 AM
Catheter Precision Inc. (NYSE American: $VTAK ) Nasdaq/NYSE Stocks Ignite Multiple Buzzers ( $AVTX, $SPCB, $INTZ )
https://www.barchart.com/story/news/21010426/...-spcb-intz
There are a large number of stock categories that could be of interest to investors, and one of those could well be the ones trading under $1. Here is a look at three of those.
Catheter Precision Inc. (NYSE American: VTAK) Stock Is In Play On Multiple Buzzers
Investors are often on the lookout for innovative companies, and at this point, Catheter Precision Inc. (NYSE American: VTAK) is a company that they could look into closely. The United States-based medical device firm is focused on launching new products into the market for the purpose of improving the treatment of cardiac arrhythmias.
The company is involved in the development of path-breaking technology meant for facilitating electrophysiology procedures. It seeks to do so through regular collaborations with physicians and progressively advancing its products. It had originally been incorporated as Ra Medical Systems Inc. in 2018, but in August 2023, it changed its name to the present one.
Here are a few upcoming events for Catheter Precision:
The company will attend the 18th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology and Therapy, which will be held Friday and Saturday, October 13–14, 2023, at the Bellevue Hotel Philadelpia.
Secondly, the company would be in attendance at the 18th Annual International VT Symposium 2023 that would be held in Philadelphia, Pennsylvania. The company noted that it would not only have the opportunity to peruse the latest advancements in clinical sciences but also get to showcase its products, VIVO and LockeT. The company would also be in attendance at the Seventh Annual SCRN Meeting on October 19 and October 20 in Washington, DC. Catheter Precision noted that it was going to be a major opportunity for it to showcase its VIVO and LockeT products.
At the third event, the Director of Electrophysiology at Penn Presbyterian Medical Center, Dr. Benjamin D'Souza, would make a presentation about his experiences with VIVO technology. The session would be titled “Noninvasive, pre-procedure 3D mapping for robotic ventricular ablations”.
Last but certainly not least, the clinical data with regards to the VIVO platform would be presented at the Irish Cardiac Society's 74th Annual Scientific Meeting, which would take place from October 12 to October 14. The moderate poster at the event, "Testing the validity of non-invasive PVC mapping technology VIVO: View Into Ventricular Onset with Patients Undergoing Invasive PVC Ablation: A Single Center Experience,", would be presented by Professor Szeplaki and his team.
Avalo Therapeutics (NASDAQ:AVTX) could well be one of the major names to follow in the category following the developments on September 26. At the time, Avalo Therapeutics announced that it had been successful in paying off the rest of its $35 debt that it owed to Horizon Technology Finance Corporation. It was a major new milestone for the company since it did not only demonstrate its commitment to a stable financial footing but also provided a way forward for speeding up future growth.
The company would be able to move ahead with its plans regarding many of its innovative drug candidates. Avalo Therapeutics’ Chief Executive Officer and Chairman of the Board, Dr. Garry A. Neill, noted that the elimination of the debt load was a testament to the hard work that had been put in by the company’s team.
SuperCom (NASDAQ:SPCB) is a worldwide Internet of Things, e-government, and cybersecurity solutions player. On September 21, SuperCom announced that it had managed to get a national program with the Finnish government.
As per the agreement, the company’s Domestic Violence Monitoring Solution would be deployed. The product is a key constituent of the PureSecurity Electronic Monitoring (EM) suite. It was a significant new milestone for the company after it had managed to launch an EM project earlier in 2023 successfully in collaboration with Finland’s Ministry of Justice.
That EM project had been involved with solutions focused on incarcerated people as well as those on probation. The company noted in its news release that the primary aim of the project was to empower the authorities in Finland and provide safety to victims of domestic violence.
Intrusion Inc. (NASDAQ: INTZ) The company, which is a leading player in the cyber-attack prevention solutions space, came into focus this morning following a key announcement. Intrusion Inc. announced that it had bagged an agreement worth $5 million with a major telecom provider. By way of the agreement, the company would be responsible for providing an intrusion shield to the above-mentioned client.
The award would entail a phase-wise rollout of the product and would begin in the fourth quarter of 2023. It would build upon the pilot in the first quarter of 2023 that had proven to be successful. The agreement had been signed for five years, and provisions had been put in place for expanding the use of the intrusion shield. Hence, there is also the prospect of generating further revenues once the agreed-upon projects are completed. In the third fiscal quarter, the company signed four other new contracts, all of which are expected to grow.
https://www.barchart.com/story/news/21010426/...-spcb-intz
There are a large number of stock categories that could be of interest to investors, and one of those could well be the ones trading under $1. Here is a look at three of those.
Catheter Precision Inc. (NYSE American: VTAK) Stock Is In Play On Multiple Buzzers
Investors are often on the lookout for innovative companies, and at this point, Catheter Precision Inc. (NYSE American: VTAK) is a company that they could look into closely. The United States-based medical device firm is focused on launching new products into the market for the purpose of improving the treatment of cardiac arrhythmias.
The company is involved in the development of path-breaking technology meant for facilitating electrophysiology procedures. It seeks to do so through regular collaborations with physicians and progressively advancing its products. It had originally been incorporated as Ra Medical Systems Inc. in 2018, but in August 2023, it changed its name to the present one.
Here are a few upcoming events for Catheter Precision:
The company will attend the 18th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology and Therapy, which will be held Friday and Saturday, October 13–14, 2023, at the Bellevue Hotel Philadelpia.
Secondly, the company would be in attendance at the 18th Annual International VT Symposium 2023 that would be held in Philadelphia, Pennsylvania. The company noted that it would not only have the opportunity to peruse the latest advancements in clinical sciences but also get to showcase its products, VIVO and LockeT. The company would also be in attendance at the Seventh Annual SCRN Meeting on October 19 and October 20 in Washington, DC. Catheter Precision noted that it was going to be a major opportunity for it to showcase its VIVO and LockeT products.
At the third event, the Director of Electrophysiology at Penn Presbyterian Medical Center, Dr. Benjamin D'Souza, would make a presentation about his experiences with VIVO technology. The session would be titled “Noninvasive, pre-procedure 3D mapping for robotic ventricular ablations”.
Last but certainly not least, the clinical data with regards to the VIVO platform would be presented at the Irish Cardiac Society's 74th Annual Scientific Meeting, which would take place from October 12 to October 14. The moderate poster at the event, "Testing the validity of non-invasive PVC mapping technology VIVO: View Into Ventricular Onset with Patients Undergoing Invasive PVC Ablation: A Single Center Experience,", would be presented by Professor Szeplaki and his team.
Avalo Therapeutics (NASDAQ:AVTX) could well be one of the major names to follow in the category following the developments on September 26. At the time, Avalo Therapeutics announced that it had been successful in paying off the rest of its $35 debt that it owed to Horizon Technology Finance Corporation. It was a major new milestone for the company since it did not only demonstrate its commitment to a stable financial footing but also provided a way forward for speeding up future growth.
The company would be able to move ahead with its plans regarding many of its innovative drug candidates. Avalo Therapeutics’ Chief Executive Officer and Chairman of the Board, Dr. Garry A. Neill, noted that the elimination of the debt load was a testament to the hard work that had been put in by the company’s team.
SuperCom (NASDAQ:SPCB) is a worldwide Internet of Things, e-government, and cybersecurity solutions player. On September 21, SuperCom announced that it had managed to get a national program with the Finnish government.
As per the agreement, the company’s Domestic Violence Monitoring Solution would be deployed. The product is a key constituent of the PureSecurity Electronic Monitoring (EM) suite. It was a significant new milestone for the company after it had managed to launch an EM project earlier in 2023 successfully in collaboration with Finland’s Ministry of Justice.
That EM project had been involved with solutions focused on incarcerated people as well as those on probation. The company noted in its news release that the primary aim of the project was to empower the authorities in Finland and provide safety to victims of domestic violence.
Intrusion Inc. (NASDAQ: INTZ) The company, which is a leading player in the cyber-attack prevention solutions space, came into focus this morning following a key announcement. Intrusion Inc. announced that it had bagged an agreement worth $5 million with a major telecom provider. By way of the agreement, the company would be responsible for providing an intrusion shield to the above-mentioned client.
The award would entail a phase-wise rollout of the product and would begin in the fourth quarter of 2023. It would build upon the pilot in the first quarter of 2023 that had proven to be successful. The agreement had been signed for five years, and provisions had been put in place for expanding the use of the intrusion shield. Hence, there is also the prospect of generating further revenues once the agreed-upon projects are completed. In the third fiscal quarter, the company signed four other new contracts, all of which are expected to grow.
(0)
(0)Ra Medical Systems Inc. (RMED) Stock Research Links
Scroll down for more posts ▼